menu
    • menu
    [{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ellipses Pharma Presents Design of Newly Initiated Phase 1\/2a Trial of Vosilasarm (EP0062) at SABCS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Vosilasarm","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ellipses Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses P.."},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ellipses Announces First Patient Dosed with EP0031, a Next Generation Selective RET Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"EP0031","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses P.."},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ellipses Pharma Announces FDA Approval of IND Application for EP0042 for Patients With Acute Myeloid Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"EP0042","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses P.."},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ellipses Pharma: EP0042 Receives Orphan Drug Designation from the US Food and Drug Administration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"EP0042","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses P.."},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Kelun-Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ellipses Pharma Announces Intent to Accelerate Clinical Programme Following \u2018Encouraging\u2019 Data on Next Generation Selective RET Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"A400","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Kelun-Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses P.."},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ellipses' Next Generation Selective RET Inhibitor EP0031\/A400 Cleared to Start Phase 2","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"EP0031","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses P.."}]

    Find Clinical Drug Pipeline Developments & Deals by Ellipses Pharma

    Menu

    Ellipses Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ellipses Pharma

                            U.S.A arrow
                            26th North American ISSX
                            Not Confirmed

                            Ellipses Pharma

                            U.S.A arrow
                            26th North American ISSX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP0031

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ellipses' Next Generation Selective RET Inhibitor EP0031/A400 Cleared to Start Phase 2

                            Details : EP0031 is a potent next-generation selective RET inhibitor that has been granted fast track designation by the FDA for the potential treatment of RET-fusion positive non-small cell lung cancer (NSCLC).

                            Product Name : EP0031

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 01, 2024

                            Lead Product(s) : EP0031

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ellipses Pharma

                            U.S.A arrow
                            26th North American ISSX
                            Not Confirmed

                            Ellipses Pharma

                            U.S.A arrow
                            26th North American ISSX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : A400

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Partner/Sponsor/Collaborator : Kelun-Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ellipses Pharma Announces Intent to Accelerate Clinical Programme Following ‘Encouraging’ Data...

                            Details : EP0031 is a potent next generation SRI with broad activity against common RET-altered tumour and mutations, including solvent front resistance mutations.

                            Product Name : EP0031

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 05, 2023

                            Lead Product(s) : A400

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Partner/Sponsor/Collaborator : Kelun-Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ellipses Pharma

                            U.S.A arrow
                            26th North American ISSX
                            Not Confirmed

                            Ellipses Pharma

                            U.S.A arrow
                            26th North American ISSX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP0042

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ellipses Pharma: EP0042 Receives Orphan Drug Designation from the US Food and Drug Administration

                            Details : EP0042 is a dual FLT3 and aurora kinase inhibitor under development as a new treatment for AML patients who have developed FLT3 inhibitor resistance. Aurora kinase has been shown to overcome acquired resi...

                            Product Name : EP0042

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 14, 2023

                            Lead Product(s) : EP0042

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ellipses Pharma

                            U.S.A arrow
                            26th North American ISSX
                            Not Confirmed

                            Ellipses Pharma

                            U.S.A arrow
                            26th North American ISSX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP0042

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ellipses Pharma Announces FDA Approval of IND Application for EP0042 for Patients With Acute Myelo...

                            Details : EP0042 is a dual FLT3 and Aurora kinase inhibitor under development as a new treatment for AML patients who have developed FLT3 inhibitor resistance. Aurora kinase has been shown to overcome acquired resi...

                            Product Name : EP0042

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 01, 2023

                            Lead Product(s) : EP0042

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ellipses Pharma

                            U.S.A arrow
                            26th North American ISSX
                            Not Confirmed

                            Ellipses Pharma

                            U.S.A arrow
                            26th North American ISSX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP0031

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ellipses Announces First Patient Dosed with EP0031, a Next Generation Selective RET Inhibitor

                            Details : EP0031 is an SRI which aims to address the unmet need for patients with RET-altered tumours (Non-Small Cell Lung Cancer (NSCLC), medullary thyroid and other RET-altered tumours) who have progressed on fir...

                            Product Name : EP0031

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 14, 2022

                            Lead Product(s) : EP0031

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ellipses Pharma

                            U.S.A arrow
                            26th North American ISSX
                            Not Confirmed

                            Ellipses Pharma

                            U.S.A arrow
                            26th North American ISSX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vosilasarm

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ellipses Pharma Presents Design of Newly Initiated Phase 1/2a Trial of Vosilasarm (EP0062) at SABC...

                            Details : EP0062 (vosilasarm) is an oral, non-steroidal, selective androgen receptor modulator (SARM) currently being developed for the treatment of AR+/HER2-/ER+ advanced breast cancer.

                            Product Name : EP0062

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 02, 2022

                            Lead Product(s) : Vosilasarm

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth